|
April 2011 – March 2013 n(%)
|
All IPC MRSA data
|
IPC-ProvLab matched data
|
p value*
|
|---|
|
n = 4818
|
n = 2211
|
|---|
| |
Clinical n = 1569 (32.7)
|
Screening n = 3249 (67.4)
|
Clinical n = 1393 (63.0)
|
Screening n = 818 (37.0)
|
< 0.05
|
|
Gender
| | | | |
0.25
|
|
Male
|
825 (52.6)
|
1699 (52.3)
|
724 (52.0)
|
446 (54.5)
|
|
Age (Years)
| | | | |
< 0.05
|
|
Mean Age (±SD)
|
57 (25.4)
|
66 (22.8)
|
56 (25.1)
|
63 (22.6)
|
|
Median Age (IQR)
|
61 (18.1)
|
73 (11.4)
|
59 (18.2)
|
67 (14.9)
|
|
Case Classification
| | | | | |
|
Hospital Acquired
|
645 (41.1)
|
1077 (33.1)
|
578 (41.5)
|
192 (23.5)
|
< 0.01**
|
|
Healthcare
|
326 (20.8)
|
978 (30.1)
|
277 (19.9)
|
276 (33.7)
|
< 0.04**
|
|
Associated
| | | | | |
|
Community Acquired
|
598 (38.1)
|
1194 (36.7)
|
538 (38.6)
|
350 (42.8)
|
< 0.01**
|
|
Facility Bed Size
| | | | | |
|
>500
|
681 (43.4)
|
1847 (56.8)
|
621 (44.6)
|
460 (56.2)
|
0.75
|
|
251–500
|
285 (18.2)
|
495 (15.2)
|
245 (17.6)
|
144 (17.6)
|
0.1
|
|
100–250
|
233 (14.9)
|
334 (10.3)
|
210 (15.1)
|
87 (10.6)
|
0.76
|
|
<100
|
370 (23.6)
|
573 (17.6)
|
317 (22.8)
|
127 (15.5)
|
0.15
|
|
Severity
| | | | | |
|
Infected
|
1432 (91.3)
|
n/a
|
1274 (91.5)
|
n/a
|
0.86
|
|
Clinical Culture Site
| | | | | |
|
Blood
|
142 (9.1)
|
n/a
|
130 (9.3)
|
n/a
|
0.79
|
|
Other Sterile
|
89 (5.7)
| |
88 (6.3)
| |
0.45
|
|
Skin/Soft Tissue
|
947 (60.4)
| |
830 (59.6)
| |
0.67
|
|
Infected Device
|
35 (2.2)
| |
29 (2.1)
| |
0.78
|
|
Respiratory
|
193 (12.3)
| |
172 (12.3)
| |
0.97
|
|
Urine
|
163 (10.4)
| |
144 (10.3)
| |
0.96
|
- All incident IPC MRSA cases can be identified from clinical and screening isolates. Matched clinical isolates from the ProvLab data repository were used as the surrogate molecular type for IPC cases identified from “screening” cultures
- *Tests of significance compare the “screening” populations, except for Clinical Culture site data
- **Bonferroni correction adjusted level of significance (α = 0.017) used to consider multiple comparisons with mutually exclusive groups
